Much of Glenn Greenwald's reporting on NSA programs was published by The Guardian. Now, he's starting a new site. Click the photo to see his interview with Brian Stelter.
NEW YORK (CNNMoney) Glenn Greenwald, the reporter who broke news of U.S. government surveillance in The Guardian newspaper last year, suggested new revelations are to come when he launches an independent news site this week.Greenwald and other investigative journalists are set to launch digital magazines with First Look Media, a venture funded by eBay (EBAY, Fortune 500) founder Pierre Omidyar. Omidyar wrote in a blog post on Thursday that "the site's staff has already uncovered a host of new and disturbing revelations in the NSA documents."
In an interview on CNN's "Reliable Sources" on Sunday, Greenwald said his new stories would start to appear online early this week. He dropped hints that he and his colleagues have come into contact with sources besides Edward Snowden, the former National Security Agency contractor who provided classified documents detailing secret surveillance programs last year.
Top 10 Performing Stocks To Invest In 2015: Johnson Matthey PLC (JMAT)
Johnson Matthey Plc is a global specialty chemicals company operating in three divisions: Environmental Technologies, Precious Metal Products and Fine Chemicals. Environmental Technologies is a supplier of catalysts and related technologies for applications, such as pollution control, cleaner fuel, hydrocarbons and the hydrogen economy. Precious Metal Products��activities comprise the marketing, distribution, refining and recycling of platinum group metals (pgms), fabrication of products using precious metals and related materials, manufactures pgm and base metal catalysts and pgm chemicals. Fine Chemicals is a supplier of active pharmaceutical ingredients, fine chemicals and other specialty chemical products and services to chemical and pharmaceutical industry�� customer supplier of catalysts. In March 2012, Endo Pharmaceuticals Holdings Inc. acquired U.S. patent 7,851,482 B2 for oxymorphone hydrochloride from the Company. In March 2013, the Company acquired Formox AB. Advisors' Opinion:- [By Inyoung Hwang]
Atos declined 3.5 percent after an investor cut its stake in the company. Intermediate Capital Group Plc lost 3.5 percent after Numis Securities Ltd. lowered its rating on the money manager. European Aeronautic, Defence & Space Co. slid 1.2 percent after UBS AG removed it from its recommended list of stocks. Johnson Matthey Plc (JMAT) climbed 3.6 percent after reporting a profit increase in the first half of the year.
- [By Sofia Horta e Costa]
Barclays Plc (BARC) fell to a one-month low as Sumitomo Mitsui Banking Corp. sold a stake in the lender. Fiat SpA lost 6.5 percent as Chrysler Group LLC went in for a vehicle recall. France Telecom SA (FTE) rose after its Orange Business Services unit won a five-year deal to deploy a private network for Heineken NV. Johnson Matthey Plc (JMAT) jumped to its highest price in at least 23 years after posting full-year profit that beat estimates.
- [By Sarah Jones]
Barclays Plc (BARC) led a selloff by U.K. lenders as Sumitomo Mitsui Financial Group Inc. sold half of its stake in the bank. EasyJet Plc (EZJ) lost 4.1 percent as the carrier reported passenger numbers for May. Johnson Matthey Plc (JMAT) rallied 6.3 percent after posting pretax profit that beat analysts��estimates.
Hot Healthcare Equipment Stocks To Invest In Right Now: Seattle Genetics Inc.(SGEN)
Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Advisors' Opinion:- [By Roberto Pedone]
One biotechnology player that insiders are snapping up a huge amount of stock in here is Seattle Genetics (SGEN), which develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Insiders are buying this stock into huge strength, since shares are up sharply by 72% so far in 2013.
Seattle Genetics has a market cap of $4.9 billion and an enterprise value of $4.5 billion. This stock trades at a premium valuation, with a price-to-sales of 19.09 and a price-to-book of 21.65. Its estimated growth rate for this year is -37%, and for next year it's pegged at -6.3%. This is a cash-rich company, since the total cash position on its balance sheet is $373.85 million and its total debt is zero.
A director just bought 1,005,901 shares, or about $43.44 million worth of stock, at $42.31 to $43.98 per share.
From a technical perspective, SGEN is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares dropping from its high of $45.37 to its intraday low of $39.85 a share. During that move, shares of SGEN have been consistently making lower highs and lower lows, which is bearish technical price action.
If you're bullish on SGEN, then I would look for long-biased trades as long as this stock is trending above its 200-day of $38.40 or above more near-term support at $36.79 and then once it takes out its 50-day at $41.02 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 856,995 shares. If we get that move soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $45.37 $46.48 a share. Any high-volume move above those levels will then give SGEN a chance to tag its 52-week high at $49.23 a share.
- [By Lee Jackson]
While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.
- [By Henry Kawabe]
A number of analysts believe the stock of the biotech company Seattle Genetics (SGEN) has risen too high too quickly to support its current price, and have issued much lower target prices on the stocks than where it currently sits. On Thursday August 1st, Analysts at Cantor Fitzgerald issued a target price of $24 a share with a "sell" recommendation as they see the potential downside of the stock could drop 40.77% from its July 31st close. Previously, on June 10th, Zacks downgraded the stock and placed a price target of $41.20 per share. In May, analysts at UBS AG issued a price target from $30.00 to $36.00 giving the stock a "neutral" rating, while analysts at Leerink Swann issued a price target of $42.00. So far, the analysts have been wrong as Seattle Genetics has blown past their price targets, and as of August 2nd, the stock continued to rise, closing at $43.28 per share.
Hot Healthcare Equipment Stocks To Invest In Right Now: Urban Outfitters Inc.(URBN)
Urban Outfitters Inc. operates lifestyle specialty retail stores under the Urban Outfitters, Anthropologie, Free People, Terrain, and BHLDN brand names in the United States, Canada, and Europe. Its Urban Outfitters stores sell women?s and men?s fashion apparel, footwear, accessories, and gifts, as well as apartment wares, such as rugs, pillows, shower curtains, books, candles, and novelties to young adults aged 18 to 28; and Anthropologie stores provide women?s casual apparel and accessories, shoes, gifts, and decorative items, as well as home furnishings, including furniture, rugs, lighting, antiques, table top items, and bedding to women aged 28 to 45. The company?s Free People stores primarily offer Free People branded merchandise mix of casual women?s apparel, intimates, shoes, accessories, and gifts to young contemporary women aged 25 to 30; Terrain store provides lifestyle home and garden products, antiques, live plants, flowers, wellness products, and accessori es, as well as landscape and design service solutions; and BHLDN store offers a range of weeding collections consisting of wedding gowns, bridesmaid frocks, party dresses, assorted jewelry, headpieces, footwear, lingerie, and decorations. As of January 31, 2012, it operated 197 Urban Outfitters stores, 168 Anthropologie stores, 62 Free People stores, 1 Terrain garden center, and 1 BHLDN store. The company also operates a wholesale business under the Free People brand name that distributes apparel to other retailers and department stores in the United States. In addition, it markets its brands directly to consumers through its e-commerce Websites, including urbanoutfitters.com, anthropologie.com, freepeople.com, urbanoutfitters.co.uk, urbanoutfitters.de, urbanoutfitters.fr, anthropologie.eu, shopterrain.com, and bhldn.com, as well as through its Urban Outfitters, Anthropologie, and Free People catalogs. The company was founded in 1970 and is based in Philadelphia, Pennsylvani a.
Advisors' Opinion:- [By Jon C. Ogg]
Big earnings winners: J.C. Penney Company (NYSE: JCP) up almost 6% to $14.01 despite poor earnings, Best Buy Co. (NYSE: BBY) 13% to $34.80 on its solid turnaround earnings, and Urban Outfitters Inc. (NASDAQ: URBN) up over 8% at $43.19 as it proved why it should have been a private equity buyout two years ago.
Hot Healthcare Equipment Stocks To Invest In Right Now: SINOPEC Shangai Petrochemical Company Ltd.(SHI)
Sinopec Shanghai Petrochemical Company Limited engages in the production of polypropylene compound products, polypropylene products, acrylic fiber products, petrochemical products, synthetic fibers, resins and plastics, and petroleum products in China and internationally. It also involves in the import and export of petrochemical products and equipment. The company was founded in 1972 and is based in Shanghai, the People's Republic of China. Sinopec Shanghai Petrochemical Company Limited is a subsidiary of China Petroleum & Chemical Corporation.
Advisors' Opinion:- [By Arjun Sreekumar]
Joint venture agreement with Sinopec
In February, Chesapeake entered into a joint venture agreement with China Petrochemical Corp (NYSE: SHI ) , otherwise known as Sinopec, giving the Chinese energy company a 50% interest in a substantial chunk of Chesapeake's Mississippi Lime assets. - [By GURUFOCUS]
In August, Apache (APA) announced that it agreed to sell a 33% stake in its Egyptian oil and gas business to Sinopec (SHI) for $3.1 billion. This price equated to $34 per barrel of proved reserves, or a significant premium to the valuation of Apache common of about $15 per barrel prior to the announcement of the transaction. Given the recent political turmoil in Egypt, we were pleasantly surprised at the higher
- [By Arjun Sreekumar]
A distressed seller's woes
But that prospect looks tenuous, as recent asset sales have been quite disappointing. For instance, Chesapeake received less than a third of the price-per-acre value it thought its Mississippi Lime assets were worth when it gave Chinese oil giant Sinopec (NYSE: SHI ) a 50% stake in them.
Hot Healthcare Equipment Stocks To Invest In Right Now: Companhia de Bebidas das Americas - AmBev(ABV)
Companhia de Bebidas das Americas?Ambev engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, malt, and other non-alcoholic and non-carbonated products in the Americas. It also sells bottled water, isotonics, and ready-to-drink teas. The company provides its products under the brand names of Skol, Brahma, Antarctica, Guarana Antarctica, Gatorade, Brahva, Brahva Beats, Extra, Brahma Light, Brahma Ice, Quilmes, Stella Artois, Red Rock, Pepsi-Cola, Seven UP, Zenda, Concordia, Triple Kola, Quilmes Cristal, Brahma, Andes, Pacena, Taquina, Huari, Becker, Baltica, Pilsen, Patricia, Labatt Blue, Alexander Keith?s, and Kokanee. It has a licensing agreement with Anheuser-Busch, Inc. to produce, bottle, distribute, and sell Budweiser products in Canada and Paraguay. Companhia de Bebidas das Americas?Ambev distributes its products through direct distribution system and third-party distributors. The company was founded in 1888 and is headquarter ed in Sao Paulo, Brazil. Companhia de Bebidas das Americas?Ambev is a subsidiary of Interbrew International B.V.
Advisors' Opinion:- [By Robert Martin]
South Africa, China, Mexico and Brazil collectively make up 68% of ECON�� holdings. The top three holdings are Naspers LTD (NPSNY) at 10%, AmBev (ABV) at 8% and FEMSA (FMX) at 5.6%.
Hot Healthcare Equipment Stocks To Invest In Right Now: Electronic Arts Inc (EA)
Electronic Arts Inc., incorporated in 1982, develops, markets, publishes and distributes game software content and services that can be played by consumers on a variety of video game machines and electronic devices (platforms). Its offers products, such as video game consoles, such as the Sony PLAYSTATION 3, Microsoft Xbox 360 and Nintendo Wii; personal computers, including the Apple Macintosh (the Company refers to personal computers and the Macintosh together as PCs); mobile devices, such as the Apple iPhone and Google Android compatible phones; tablets and electronic readers, such as the Apple iPad and the Amazon Kindle, and Internet, including social networking sites, such as Facebook. In August 2011, it acquired PopCap Games Inc. (PopCap), a developer of casual games for mobile devices, tablets, PCs, and social networking sites.
The Company has created, licensed and acquired a portfolio of brands, which span a diverse range of categories, including action-adventure, casual, family, fantasy, first-person shooter, horror, science fiction, role-playing, racing, simulation, social, sports, and strategy. The Company�� portfolio of brands includes wholly owned brands, such as Battlefield, Mass Effect, Need for Speed, The Sims, Bejeweled, and Plants v. Zombies. Its portfolio also includes sports-based brands, such as Madden NFL and FIFA, and titles-based on other brands, such as Star Wars: The Old Republic. It provides a variety of online-delivered products and services, including through its Origin platform. Its packaged goods products are also available through direct online download through the Internet. The Company also offers online-delivered content and services that are add-ons or related to its packaged goods products, such as additional game content or enhancements of multiplayer services. It provides other games, content and services that are available only via electronic delivery, such as Internet-only games and game services, and games for mobile devices.
The Comp! any operates development studios (which develop products and perform other related functions) in North America, Europe, Asia and Australia. It also engages third parties to assist with the development of its games at their own development and production studios. Internationally, the Company conducts business through its international headquarters in Switzerland and has wholly owned subsidiaries worldwide, including offices in Europe, Australia, Asia and Latin America. The Company�� studios and development teams are organized around its Label structure. Each Label operates globally with dedicated game development and marketing teams. These Labels are supported by the Company�� Global Publishing Organization that is responsible for the distribution, sales, and marketing of its products, including planning, operations, and manufacturing functions.
EA Games
EA Games is home to a number of the Company�� studios and development teams, which together create a portfolio of games and related content and services marketed under the EA brand in categories, such as action-adventure, role playing, racing and first-person shooter games. The EA Games portfolio includes a number of franchises, such as Battlefield, Dead Space, Medal of Honor and Need for Speed. EA Games titles are developed primarily at the following EA studios, Criterion, DICE, EA Los Angeles, Visceral, and EA Montreal. EA Games also contracts with external game developers, to provide these developers with a variety of services, including development assistance, publishing, and distribution of their games.
EA SPORTS
EA SPORTS develops a collection of sports-based video games and related content and services marketed under the EA SPORTS brand. EA SPORTS games range from simulated sports titles with realistic graphics based on real-world sports leagues, players, events and venues to more casual games with arcade-style gameplay and graphics. The Company�� EA SPORTS franchises include FIFA, Fig! ht Night,! Madden NFL, NCAA Football, NHL Hockey, and Tiger Woods PGA Tour. EA SPORTS games are developed primarily at the Company�� EA Canada studio in Burnaby, British Columbia, and its EA Tiburon studio located in Orlando, Florida.
BioWare
BioWare develops role-playing games, focused on stories, characters and worlds to discover. BioWare�� portfolio includes the MMO role-playing game Star Wars: The Old Republic and the Mass Effect and Dragon Age franchises. BioWare operates in Texas, California, Canada and Ireland.
Maxis
Maxis (formerly EA Play) are focused on creating games and related content and services for a mass audience. Maxis products include wholly owned franchises, such as The Sims, SimCity, MySims, and Spore. During the fiscal year ended March 31, 2012 (fiscal 2012), the Company released titles in The Sims 3 franchise, and together with Playfish, The Sims Social game on Facebook. Maxis oversees internal studios and development teams located in California, Utah, Beijing, China and Guildford, England, and works with third-party developers.
PopCap
PopCap develops easy-to-learn games. PopCap games, including Bejeweled, Plants vs. Zombies, Zuma, Peggle, and Bookworm are gameplays. PopCap games are developed primarily in Seattle, Washington.
Social/Mobile Studios
The Company�� Social/Mobile studios is focused on developing interactive games for play on mobile devices and Internet platforms, including social networking sites, such as Facebook. Through EA Mobile, the Company is a global publisher of games for mobile devices. Its customers purchase and download the Company�� games through a mobile carrier�� e-commerce service and mobile application storefronts accessed directly from their mobile devices. EA Mobile develops games for mobile devices at studios located in the United States, Canada, Romania, Australia, India and Korea. Through Playfish, it offers free-to-play social games, in! cluding T! he Sims Social, Pet Society, EA Sports FIFA Superstars and Madden NFL Superstars that can be played on platforms, such as Facebook, Google, iPhone and Android. Playfish generates revenue through sales of digital content and Internet-based advertising.
The Company, through its Pogo online service, offers games, such as card, puzzle and word games on www.pogo.com, as well as on Facebook and other platforms. In addition to paid subscriptions, Pogo also generates revenue through Internet-based advertising and sales of digital content. In addition, it has a licensing agreement with Hasbro, which provides the Company with the rights to create digital games for all platforms based on most of Hasbro�� toy and game intellectual properties, including MONOPOLY, SCRABBLE (for United States and Canada), YAHTZEE (excluding the Nordic countries), NERF, and LITTLEST PET SHOP. Hasbro games are developed by its EA Mobile, Pogo and Social studios.
The Company competes with Activision Blizzard, Take-Two Interactive, THQ, Ubisoft, Disney, Capcom Mobile, DeNA, Gameloft, Glu Mobile, Gree, Rovio, Zynga, Big Fish, Nexon, Tencent and Facebook.
Advisors' Opinion:- [By Dan Caplinger]
Electronic Arts (NASDAQ: EA ) , up 30.6%
Like AMD, EA got some big news during May, in the form of a partnership with Disney to produce video games based on the Star Wars franchise. That, in combination with hopes about the potential impact of new gaming consoles on EA's core business, got investors excited about the stock once more. Yet as Fool contributor Rick Munarriz points out, EA's earnings in its previous quarter included some concerns about the potential for slowing growth at the company, and despite raising its guidance for the coming fiscal year, the big question long-term is whether EA will really get that much profit out of Star Wars -- or whether the recent buyer of Lucasfilm will keep most of the proceeds for itself. - [By Anora Mahmudova]
Electronic Arts Inc. (EA) �shares surged 12% after CRT Capital initiated coverage of the company with a buy rating , according to Analyst Ratings Network.
- [By Steve Symington]
On Tuesday, both�Hasbro (NASDAQ: HAS ) and�Electronic Arts (NASDAQ: EA ) stock rose slightly after the companies announced a new four-year agreement, under which EA will develop mobile games based on several of Hasbro's most popular gaming brands.
Hot Healthcare Equipment Stocks To Invest In Right Now: SciClone Pharmaceuticals Inc.(SCLN)
SciClone Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People?s Republic of China and internationally. Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, primarily China, the Pacific Rim, Latin America, eastern Europe, and the Middle East. The company markets and sells ZADAXIN principally through its distributors. It is also developing SCV-07, which is in Phase 2 clinical trials for the treatment of oral mucositis and hepatitis C virus. In addition, the company markets partnered products in China, including Depakine, an anti-convulsant; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia; and Aggrastat, a cardiology product. SciClone Pharmaceuticals also has commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam. The company was founded in 1989 and is headquartered in Foster City, California.
Advisors' Opinion:- [By Monica Gerson]
SciClone Pharmaceuticals (NASDAQ: SCLN) is expected to report its Q4 earnings at $0.15 per share on revenue of $38.30 million.
Essex Rental (NASDAQ: ESSX) is projected to post a Q4 loss at $0.10 per share on revenue of $22.55 million.
No comments:
Post a Comment